



US006653140B2

(12) **United States Patent**
Otvos

(10) **Patent No.:** **US 6,653,140 B2**
(45) **Date of Patent:** **Nov. 25, 2003**

(54) **METHODS FOR PROVIDING PERSONALIZED LIPOPROTEIN-BASED RISK ASSESSMENTS**

(75) Inventor: **James D. Otvos**, Apex, NC (US)

(73) Assignee: **Liposcience, Inc.**, Raleigh, NC (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **10/294,262**

(22) Filed: **Nov. 14, 2002**

(65) **Prior Publication Data**

US 2003/0119194 A1 Jun. 26, 2003

Related U.S. Application Data

(63) Continuation of application No. 09/258,740, filed on Feb. 26, 1999, now abandoned.

(51) **Int. Cl.**⁷ **G01N 33/92**

(52) **U.S. Cl.** **436/71; 436/13; 436/16; 436/173**

(58) **Field of Search** **436/13, 16, 71, 436/173**

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,933,844 A 6/1990 Otvos 364/413.08
5,343,389 A 8/1994 Otvos 364/413.09

FOREIGN PATENT DOCUMENTS

WO WO 91/10128 7/1991
WO WO 93/03450 2/1993

OTHER PUBLICATIONS

News Release, *Radio signals give new spectrum for cholesterol lipoprotein readings*, American Heart Association Journal Report (Jul. 9, 1998).

Brochure, *New Technology Detects Hidden Risk of Heart Disease; NMR Lipoprofile™ Seen as Powerful New Tool in*

Disease Assessment and Management, LipoMed, Inc., Raleigh, NC (Mar. 26, 1998).

Abstracts, Supplement to *Circulation*, Journal of the American Heart Association Abstracts for the 71st Scientific Sessions (11/98).

Otvos, *Measurement of Lipoprotein Subclass Profiles by NMR Spectroscopy*, Handbook of Lipoprotein Testing, pp. 497–508 (AACC Press, 1997).

Freedman et al., *Relation of Lipoprotein Subclasses as Measured by Proton Nuclear Magnetic Resonance Spectroscopy to Coronary Artery Disease, Arterioscler Thromb Vasc Biol.* 18, pp. 1046–1053 (Jul. 1998).

Wilson et al., *Prediction of Coronary Heart Disease Using Risk Factor Categories*, American Heart Association, Inc. pp. 1837–1847 (5/98).

National Cholesterol Education Program, “Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II),” *Circulation* 1994, vol. 89, No. 3 (pp. 1329–1445 (Mar. 1994).

Lamarche et al., “Apolipoprotein A-I and B Levels and the Risk of Ischemic Heart Disease During a Five-Year Follow-up of Men in the Québec Cardiovascular Study,” *Circulation*, vol. 94, No. 3, pp. 273–278 (Aug. 1, 1996).

(List continued on next page.)

Primary Examiner—Jill Warden

Assistant Examiner—Yelena Gakh

(74) *Attorney, Agent, or Firm*—Myers Bigel Sibley & Sajovec PA

(57) **ABSTRACT**

Methods for assessing a patient’s risk of having or developing coronary heart disease based on lipoprotein measurements measure and identify values for lipoprotein subclass constituents and analyze according to predetermined test criteria to identify when there is an increased and/or decreased risk of having and/or developing coronary heart disease associated with the measured lipoprotein subclass constituent values.

23 Claims, 11 Drawing Sheets

